Insulin and Alzheimer's disease: Untangling the web

Journal of Alzheimer's Disease

Volumn 33, Issue SUPPL. 1, 2013, Pages

  Craft, Suzanne ^a,b   Cholerton, Brenna ^a,b   Baker, Laura D ^a,b  

^a VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; diabetes; insulin; network analysis

Indexed keywords

AMYLOID BETA PROTEIN; EXENDIN 4; GASTRIC INHIBITORY POLYPEPTIDE; GLUCOSE; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE;

AGING; ALZHEIMER DISEASE; BIOLOGICAL THERAPY; BRAIN FUNCTION; DIET THERAPY; DISEASE COURSE; DYSLIPIDEMIA; EXERCISE; GLUCOSE BRAIN LEVEL; GLUCOSE METABOLISM; HEART FAILURE; HUMAN; INSULIN LIKE ACTIVITY; INSULIN METABOLISM; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LONGEVITY; MEDITERRANEAN DIET; MEMORY DISORDER; NERVOUS SYSTEM INFLAMMATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW;

EID: 84872580306     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2012-129042     Document Type: Review

References (117)

1. Kaiyala KJ, Prigeon RL, Kahn SE, Woods SC, Schwartz MW (2000) Obesity induced by a high-fat diet is associated with reduced brain insulin transport in dogs. Diabetes 49, 1525-1533
2. Banks WA, Jaspan JB, Huang W, Kastin AJ (1997) Transport of insulin across the blood-brain barrier: Saturability at euglycemic doses of insulin. Peptides 18, 1423-1429
3. Baskin DG, Figlewicz DP,Woods SC, PorteDJr, DorsaDM (1987) Insulin in the brain. Annu Rev Physiol 49, 335-347
4. Baura GD, Foster DM, Porte D Jr, Kahn SE, Bergman RN, Cobelli C, Schwartz MW (1993) Saturable transport of insulin from plasma into the central nervous system of dogs in vivoA mechanism for regulated insulin delivery to the brain. J Clin Invest 92, 1824-1830
5. Abbott MA,Wells DG, Fallon JR (1999) The insulin receptor tyrosine kinase substrate p58/53 and the insulin receptor are components of CNS synapses. J Neurosci 19, 7300-7308
6. Chiu SL, Chen CM, Cline HT (2008) Insulin receptor signaling regulates synapse number, dendritic plasticity, and circuit function in vivo. Neuron 58, 708-719
7. Zhao WQ, Townsend M (2009) Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer's disease. Biochim Biophys Acta 1792, 482-496
8. Havrankova J, Roth J, Brownstein M (1978) Insulin receptors are widely distributed in the central nervous system of the rat. Nature 272, 827-829
9. Havrankova J, Schmechel D, Roth J, Brownstein M (1978) Identification of insulin in rat brain. Proc Natl Acad SciUSA 75, 5737-5741
10. Unger JW, Livingston JN, Moss AM (1991) Insulin receptors in the central nervous system: Localization, signalling mechanisms and functional aspects. Prog Neurobiol 36, 343-362
11. Grillo CA, Piroli GG, Hendry RM, Reagan LP (2009) Insulin-Stimulated translocation of GLUT4 to the plasma membrane in rat hippocampus is PI3-kinase dependent. Brain Res 1296, 35-45
12. Zhao WQ, Alkon DL (2001) Role of insulin and insulin receptor in learning and memory. Mol Cell Endocrinol 177, 125-134
13. Skeberdis VA, Lan J, Zheng X, Zukin RS, Bennett MV (2001) Insulin promotes rapid delivery of N-Methyl-Daspartate receptors to the cell surface by exocytosis. Proc Natl Acad Sci U S A 98, 3561-3566
14. Figlewicz DP, Szot P, Israel PA, Payne C, Dorsa DM (1993) Insulin reduces norepinephrine transporter mRNA in vivo in rat locus coeruleus. Brain Res 602, 161-164
15. Kopf SR, Baratti CM (1999) Effects of posttraining administration of insulin on retention of a habituation response in mice: Participation of a central cholinergic mechanism. Neurobiol Learn Mem 71, 50-61
16. Krug R, Benedict C, Born J, Hallschmid M (2010) Comparable sensitivity of postmenopausal and young women to the effects of intranasal insulin on food intake and working memory. J Clin Endocrinol Metab 95, E468-472
17. Frolich L, Blum-Degen D, Bernstein HG, Engelsberger S, Humrich J, Laufer S, Muschner D, Thalheimer A, Turk A, Hoyer S, Zochling R, Boissl KW, Jellinger K, Riederer P (1998) Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease. J Neural Transm 105, 423-438
18. Craft S, Peskind E, Schwartz MW, Schellenberg GD, Raskind M, Porte D Jr (1998) Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: Relationship to severity of dementia and apolipoprotein E genotype. Neurology 50, 164-168
19. Gil-Bea FJ, Solas M, Solomon A, Mugueta C, Winblad B, Kivipelto M, Ramirez MJ, Cedazo-Minguez A (2010) Insulin levels are decreased in the cerebrospinal fluid of women with prodomal Alzheimer's disease. J Alzheimers Dis 22, 405-413
20. Rivera E, Goldin A, Fulmer N, Tavares R, Wands J, de la Monte S (2005) Insulin and insulin-Like growth factor expression and function deteriorate with progression of Alzheimer's disease: Link to brain reductions in acetylcholine. J Alzheimers Dis 8, 247-268
21. Selkoe DJ (2008) Soluble oligomers of the amyloid betaprotein impair synaptic plasticity and behavior. Behav Brain Res 192, 106-113
22. De Felice FG, Vieira MN, Bomfim TR, Decker H, Velasco PT, Lambert MP, Viola KL, Zhao WQ, Ferreira ST, Klein WL (2009) Protection of synapses against Alzheimer's-Linked toxins: Insulin signaling prevents the pathogenic binding of Abeta oligomers. Proc Natl Acad Sci U S A 106, 1971-1976
23. Gasparini L, Gouras GK, Wang R, Gross RS, Beal MF, Greengard P, Xu H (2001) Stimulation of beta-Amyloid precursor protein trafficking by insulin reduces intraneuronal beta-Amyloid and requires mitogen-Activated protein kinase signaling. J Neurosci 21, 2561-2570
24. Lee CC, Kuo YM, Huang CC, Hsu KS (2009) Insulin rescues amyloid beta-induced impairment of hippocampal long-Term potentiation. Neurobiol Aging 30, 377-387
25. Townsend M, Mehta T, Selkoe DJ (2007) Soluble Abeta inhibits specific signal transduction cascades common to the insulin receptor pathway. J Biol Chem 282, 33305-33312
26. Ma QL, Yang F, Rosario ER, Ubeda OJ, Beech W, Gant DJ, Chen PP, Hudspeth B, Chen C, Zhao Y, Vin ters HV, Frautschy SA, Cole GM (2009) Beta-Amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-Terminal kinase signaling: Suppression by omega-3 fatty acids and curcumin. J Neurosci 29, 9078-9089
27. Cao D, Lu H, Lewis TL, Li L (2007) Intake of sucrosesweetened water induces insulin resistance and exacerbates memory deficits and amyloidosis in a transgenic mouse model of Alzheimer disease. J BiolChem282, 36275-36282
28. Ho L, QinW, Pompl PN, Xiang Z,Wang J, Zhao Z, Peng Y, Cambareri G, Rocher A, Mobbs CV, Hof PR, Pasinetti GM (2004) Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J 18, 902-904
29. Bayer-Carter JL, Green PS, Montine TJ, VanFossen B, Baker LD,Watson GS, Bonner LM, Callaghan M, Leverenz JB, Walter BK, Tsai E, Plymate SR, Postupna N, Wilkinson CW, Zhang J, Lampe J, Kahn SE, Craft S (2011) Diet intervention and cerebrospinal fluid biomarkers in amnestic mild cognitive impairment. Arch Neurol 68, 743-752
30. Hong M, Lee V (1997) Insulin and insulin-Like growth factor-1 regulate tau phosphorylation in cultured human neurons. J Biol Chem 272, 19547-19553
31. Baker LD, Cross DJ, Minoshima S, Belongia D,Watson GS, Craft S (2011) Insulin resistance and Alzheimer-Like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes. Arch Neurol 68, 51-57
32. Musen G, Jacobson AM, Bolo NR, Simonson DC, Shenton ME, McCartney RL, Flores VL, Hoogenboom WS (2012) Resting-State brain functional connectivity is altered in type 2 diabetes. Diabetes 61, 2375-2379
33. Cavanna AE, Trimble MR (2006) The precuneus: A review of its functional anatomy and behavioural correlates. Brain 129, 564-583
34. Cersosimo E, DeFronzo RA (2006) Insulin resistance and endothelial dysfunction: The road map to cardiovascular diseases. Diabetes Metab Res Rev 22, 423-436
35. Anstey KJ, Lipnicki DM, Low LF (2008) Cholesterol as a risk factor for dementia and cognitive decline: A systematic review of prospective studies with meta-Analysis. Am J Geriatr Psychiatry 16, 343-354
36. Burgess BL, McIsaac SA, Naus KE, Chan JY, Tansley GH, Yang J, Miao F, Ross CJ, van Eck M, Hayden MR, van Nostrand W, St George-Hyslop P, Westaway D, Wellington CL (2006) Elevated plasma triglyceride levels precede amyloid deposition in Alzheimer's disease mouse models with abundant A beta in plasma. Neurobiol Dis 24, 114-127
37. Sechi LA (1999) Mechanisms of insulin resistance in rat models of hypertension and their relationships with salt sensitivity. J Hypertens 17, 1229-1237
38. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, O'Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, Streit W, Strohmeyer R, Tooyoma I, Van Muiswinkel FL, Veerhuis R, Walker D, Webster S, Wegrzyniak B, Wenk G, Wyss-Coray T (2000) Inflammation and Alzheimer's disease. Neurobiol Aging 21, 383-421
39. Rogers J, Shen Y (2000) A perspective on inflammation in Alzheimer's disease. Ann N Y Acad Sci 924, 132-135
40. Hull M, Strauss S, Berger M, Volk B, Bauer J (1996) The participation of interleukin-6, a stress-inducible cytokine, in the pathogenesis of Alzheimer's disease. Behav Brain Res 78, 37-41
41. Montine TJ, Kaye JA, Montine KS, McFarland L, Morrow JD, Quinn JF (2001) Cerebrospinal fluid abeta42, tau, and f2-isoprostane concentrations in patients with Alzheimer disease, other dementias, and in age-Matched controls. Arch Pathol Lab Med 125, 510-512
42. Rosler N,Wichart I, Jellinger KA (2001) Intra vitam lumbar and post mortem ventricular cerebrospinal fluid immunoreactive interleukin-6 in Alzheimer's disease patients. Acta Neurol Scand 103, 126-130
43. Sheng JG, Bora SH, Xu G, Borchelt DR, Price DL, Koliatsos VE (2003) Lipopolysaccharide-inducedneuroinflammation increases intracellular accumulation of amyloid precursor protein and amyloid beta peptide in APPswe transgenic mice. Neurobiol Dis 14, 133-145
44. Dandona P (2002) Endothelium, inflammation, and diabetes. Curr Diab Rep 2, 311-315
45. Fishel MA, Watson GS, Montine TJ, Wang Q, Green PS, Kulstad JJ, Cook DG, Peskind ER, Baker LD, Goldgaber D, Nie W, Asthana S, Plymate SR, Schwartz MW, Craft S (2005) Hyperinsulinemia provokes synchronous increases in central inflammation and beta-Amyloid in normal adults. Arch Neurol 62, 1539-1544
46. Olefsky JM (2000) Treatment of insulin resistance with peroxisome proliferator-Activated receptor gamma agonists. J Clin Invest 106, 467-472
47. Combs CK, Johnson DE, Karlo JC, Cannady SB, Landreth GE (2000) Inflammatory mechanisms in Alzheimer's disease: Inhibition of beta-Amyloid-Stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. J Neurosci 20, 558-567
48. Delerive P, Fruchart JC, Staels B (2001) Peroxisome proliferator- Activated receptors in inflammation control. J Endocrinol 169, 453-459
49. Paik JH, Ju JH, Lee JY, Boudreau MD, Hwang DH (2000) Two opposing effects of non-Steroidal anti-inflammatory drugs on the expression of the inducible cyclooxygenase. Mediation through different signaling pathways. J Biol Chem 275, 28173-28179
50. Hirsch EC, Breidert T, Rousselet E, Hunot S, Hartmann A, Michel PP (2003) The role of glial reaction and inflammation in Parkinson's disease. Ann N Y Acad Sci 991, 214-228
51. Schmidt S, Moric E, Schmidt M, Sastre M, Feinstein DL, Heneka MT (2004) Anti-inflammatory and antiproliferative actions of PPAR-gamma agonists on T lymphocytes derived from MS patients. J Leukoc Biol 75, 478-485
52. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA (1995) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-Activated receptor gamma (PPAR gamma). J Biol Chem 270, 12953-12956
53. Watson GS, Cholerton BA, Reger MA, Baker LD, Plymate SR, Asthana S, Fishel MA, Kulstad JJ, Green PS, Cook DG, Kahn SE, Keeling ML, Craft S (2005) Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: A preliminary study. Am J Geriatr Psychiatry 13, 950-958
54. Risner ME, SaundersAM,Altman JF, Ormandy GC, Craft S, Foley IM, Zvartau-Hind ME, HosfordDA, RosesAD(2006) Efficacy of rosiglitazone in a genetically defined population with mild-To-Moderate Alzheimer's disease. Pharmacogenomics J 6, 246-254
55. Harrington C, Sawchak S, Chiang C, Davies J, Donovan C, Saunders AM, Irizarry M, Jeter B, Zvartau-Hind M, van Dyck CH, Gold M (2011) Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-To-Moderate Alzheimer's disease: Two phase 3 studies. Curr Alzheimer Res 8, 592-606
56. Gold M, Alderton C, Zvartau-Hind M, Egginton S, Saunders AM, Irizarry M, Craft S, Landreth G, Linnamagi U, Sawchak S (2010) Rosiglitazone monotherapy in mild-Tomoderate Alzheimer's disease: Results from a randomized, double-blind, placebo-controlled phase III study. Dement Geriatr Cogn Disord 30, 131-146
57. Sato T, Hanyu H, Hirao K, Kanetaka H, Sakurai H, Iwamoto T (2011) Efficacy of PPAR-gamma agonist pioglitazone in mild Alzheimer disease. Neurobiol Aging 32, 1626-1633
58. Hanyu H, Sato T, Kiuchi A, Sakurai H, Iwamoto T (2009) Pioglitazone improved cognition in a pilot study on patients with Alzheimer's disease and mild cognitive impairment with diabetes mellitus. J Am Geriatr Soc 57, 177-179
59. Hanyu H, Sato T, Sakurai H, Iwamoto T (2010) The role of tumor necrosis factor-Alpha in cognitive improvement after peroxisome proliferator-Activator receptor gamma agonist pioglitazone treatment in Alzheimer's disease. J Am Geriatr Soc 58, 1000-1001
60. Geldmacher DS, Fritsch T, McClendon MJ, Landreth G (2011) A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer disease. Arch Neurol 68, 45-50
61. Mannucci E, Monami M, Di Bari M, Lamanna C, Gori F, Gensini GF, Marchionni N (2010) Cardiac safety profile of rosiglitazone: A comprehensive meta-Analysis of randomized clinical trials. Int J Cardiol 143, 135-140
62. Moon JH, Kim HJ, Yang AH, Kim HM, Lee BW, Kang ES, Lee HC, Cha BS (2011) The effect of rosiglitazone on LRP1 expression and amyloid beta uptake in human brain microvascular endothelial cells: A possible role of a low-Dose thiazolidinedione for dementia treatment. Int J Neuropsychopharmacol 15, 135-142
63. Holscher C (2010) The role of GLP-1 in neuronal activity and neurodegeneration. Vitam Horm 84, 331-354
64. Sivertsen J, Rosenmeier J, Holst JJ, Vilsboll T (2012) The effect of glucagon-Like peptide 1 on cardiovascular risk. Nat Rev Cardiol 9, 209-222
65. Bomfim TR, Forny-Germano L, Sathler LB, Brito-Moreira J, Houzel JC, Decker H, Silverman MA, Kazi H, Melo HM, McClean PL, Holscher C, Arnold SE, Talbot K, Klein WL, Munoz DP, Ferreira ST, De Felice FG (2012) An anti-Diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- Associated Abeta oligomers. J Clin Invest 122, 1339-1353
66. Craft S, Asthana S, Cook DG, Baker LD, Cherrier M, Purganan K, Wait C, Petrova A, Latendresse S, Watson GS, Newcomer JW, Schellenberg GD, Krohn AJ (2003) Insulin dose-response effects on memory and plasma amyloid precursor protein in Alzheimer's disease: Interactions with apolipoprotein E genotype. Psychoneuroendocrinology 28, 809-822
67. Craft S, Asthana S,NewcomerJW,WilkinsonCW,Matos IT, Baker LD, Cherrier M, Lofgreen C, Latendresse S, Petrova A, Plymate S, Raskind M, Grimwood K, Veith RC (1999) Enhancement of memory in Alzheimer disease with insulin and somatostatin, but not glucose. Arch Gen Psychiatry 56, 1135-1140
68. Craft S, Newcomer J, Kanne S, Dagogo-Jack S, Cryer P, Sheline Y, Luby J, Dagogo-Jack A, Alderson A (1996) Memory improvement following induced hyperinsulinemia in Alzheimer's disease. Neurobiol Aging 17, 123-130
69. Park CR, Seeley RJ, Craft S, Woods SC (2000) Intracerebroventricular insulin enhances memory in a passive-Avoidance task. Physiol Behav 68, 509-514
70. Born J, Lange T, Kern W, McGregor GP, Bickel U, Fehm HL (2002) Sniffing neuropeptides: A transnasal approach to the human brain. Nat Neurosci 5, 514-516
71. Frey WH 2nd (2002) Intranasal delivery: Bypassing the blood-brain barrier to deliver therapeutic agents to the brain and spinal cord. Drug Deliv Technol 2, 46-49
72. Thorne RG, Pronk GJ, Padmanabhan V, Frey WH, 2nd (2004) Delivery of insulin-Like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 127, 481-496
73. Baker H, Spencer RF (1986) Transneuronal transport of peroxidase-conjugated wheat germ agglutinin (WGA-HRP) from the olfactory epithelium to the brain of the adult rat. Exp Brain Res 63, 461-473
74. Balin BJ, Broadwell RD, Salcman M, el-Kalliny M (1986) Avenues for entry of peripherally administered protein to the central nervous system in mouse, rat, and squirrel monkey. J Comp Neurol 251, 260-280
75. Broadwell RD, Balin BJ (1985) Endocytic and exocytic pathways of the neuronal secretory process and transsynaptic transfer of wheat germ agglutinin-horseradish peroxidase in vivo. J Comp Neurol 242, 632-650
76. Shipley MT (1985) Transport of molecules from nose to brain: Transneuronal anterograde and retrograde labeling in the rat olfactory system by wheat germ agglutininhorseradish peroxidase applied to the nasal epithelium. Brain Res Bull 15, 129-142
77. Kern W, Born J, Schreiber H, Fehm HL (1999) Central nervous system effects of intranasally administered insulin during euglycemia in men. Diabetes 48, 557-563
78. Francis GJ, Martinez JA, Liu WQ, Xu K, Ayer A, Fine J, Tuor UI, Glazner G, Hanson LR, Frey WH, 2nd, Toth C (2008) Intranasal insulin prevents cognitive decline, cerebral atrophy and white matter changes in murine type I diabetic encephalopathy. Brain 131, 3311-3334
79. Benedict C, Hallschmid M, Hatke A, Schultes B, Fehm HL, Born J, KernW(2004) Intranasal insulin improves memory in humans. Psychoneuroendocrinology 29, 1326-1334
80. Benedict C, Kern W, Schultes B, Born J, Hallschmid M (2008) Differential sensitivity of men and women to anorexigenic and memory-improving effects of intranasal insulin. J Clin Endocrinol Metab 93, 1339-1344
81. Hallschmid M, Benedict C, Schultes B, Born J, Kern W (2008) Obese men respond to cognitive but not to catabolic brain insulin signaling. Int J Obes (Lond) 32, 275-282
82. Stockhorst U, de Fries D, Steingrueber HJ, Scherbaum WA (2004) Insulin and the CNS: Effects on food intake, memory, and endocrine parameters and the role of intranasal insulin administration in humans. Physiol Behav 83, 47-54
83. Reger MA, Watson GS, Green PS, Baker LD, Cholerton B, Fishel MA, Plymate SR, Cherrier MM, Schellenberg GD, Frey WH, Craft S (2008) Intranasal insulin administration dose-Dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. J Alzheimers Dis 13, 323-331
84. Reger MA, Watson GS, Frey II WH, Baker LD, Cholerton B, Keeling ML, Belongia DA, Fishel MA, Plymate SR, Schellenberg GD, Cherrier MM, Craft S (2006) Effects of intranasal insulin on cognition in memory-impaired older adults: Modulation by APOE genotype. Neurobiol Aging 27, 451-458
85. Reger MA, Watson GS, Green PS, Wilkinson CW, Baker LD, Cholerton B, Fishel MA, Plymate SR, Breitner JCS, DeGroodt W, Mehta P, Craft S (2008) Intranasal insulin improves cognition and modulates beta-Amyloid in early AD. Neurology 70, 440-448
86. Craft S, Baker LD, Montine TJ, Minoshima S, Watson GS, Claxton A, Arbuckle M, Callaghan M, Tsai E, Plymate SR, Green PS, Leverenz J, Cross D, Gerton B (2012) Intranasal insulin therapy for alzheimer disease and amnestic mild cognitive impairment: A pilot clinical trial. Arch Neurol 69, 29-38
87. Hill JO,Wyatt HR, ReedGW, Peters JC (2003) Obesity and the Environment: Where do we go from here? Science 299, 853-855
88. Siri-TarinoPW, Sun Q, Hu FB, KraussRM(2010) Saturated fat, carbohydrate, and cardiovascular disease.AmJ Clin Nutr 91, 502-509
89. Salzman R, Manson JE, Griffing GT, Kimmerle R, Ruderman N, McCall A, Stoltz EI, Mullin C, Small D, Armstrong J et al. (1985) Intranasal aerosolized insulin. Mixed-Meal studies and long-Term use in type I diabetes. N Engl J Med 312, 1078-1084
90. Kanoski SE, Davidson TL (2011)Western diet consumption and cognitive impairment: Links to hippocampal dysfunction and obesity. Physiol Behav 103, 59-68
91. Panza F, FrisardiV, Capurso C, Imbimbo BP,Vendemiale G, Santamato A, D'Onofrio G, Seripa D, Sancarlo D, Pilotto A, Solfrizzi V (2010) Metabolic syndrome and cognitive impairment: Current epidemiology and possible underlying mechanisms. J Alzheimers Dis 21, 691-724
92. Cunnane SC, Plourde M, Pifferi F, B'egin M, F'eart C, Barberger-Gateau P (2009) Fish, docosahexaenoic acid and Alzheimer's disease. Prog Lipid Res 48, 239-256
93. Solfrizzi V, Frisardi V, Capurso C, D'Introno A, Colacicco AM,Vendemiale G, Capurso A, Panza F (2010) Dietary fatty acids in dementia and predementia syndromes: Epidemiological evidence and possible underlying mechanisms. Ageing Res Rev 9, 184-199
94. Cedazo-Minguez A, Wiehager B, Winblad B, Huttinger M, Cowburn RF (2001) Effects of apolipoprotein E (apoE) isoforms, beta-Amyloid (Abeta) and apoE/Abeta complexes on protein kinase C-Alpha (PKC-Alpha) translocation and amyloid precursor protein (APP) processing in human SH-SY5Y neuroblastoma cells and fibroblasts. Neurochem Int 38, 615-625
95. Takechi R, Galloway S, Pallebage-Gamarallage MM, Lam V, Mamo JC (2010) Dietary fats, cerebrovasculature integrity and Alzheimer's disease risk. Prog Lipid Res 49, 159-170
96. Schroeder JE, Richardson JC, Virley DJ (2010) Dietary manipulation and caloric restriction in the development of mouse models relevant to neurological diseases. Biochim Biophys Acta 1802, 840-846
97. Smith PJ, Blumenthal JA (2010) Diet and neurocognition: Review of evidence and methodological considerations. Curr Aging Sci 3, 57-66
98. Engelhart MJ, Geerlings MI, Ruitenberg A, Van Swieten JC, Hofman A,Witteman JC, BretelerMM(2002) Diet and risk of dementia: Does fat matter? The Rotterdam Study. Neurology 59, 1915-1921
99. Freund-Levi Y, Eriksdotter-Jonhagen M, Cederholm T, Basun H, Faxen-Irving G, Garlind A, Vedin I, Vessby B, Wahlund LO, Palmblad J (2006) Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: A randomized double-blind trial. Arch Neurol 63, 1402-1408
100. F'eart C, Samieri C, Rondeau V, Amieva H, Portet F, Dartigues J-F, Scarmeas N, Barberger-Gateau P (2009) Adherence to a Mediterranean diet, cognitive decline, and risk of dementia. JAMA 302, 638-648
101. Gu Y, Nieves JW, Stern Y, Luchsinger JA, Scarmeas N (2010) Food combination and Alzheimer disease risk: A protective diet. Arch Neurol 67, 699-706
102. Scarmeas N, Stern Y, Mayeux R, Manly JJ, Schupf N, Luchsinger JA(2009) Mediterranean diet and mild cognitive impairment. Arch Neurol 66, 216-225
103. Baker LD, Frank LL, Foster-Schubert K, Green PS, Wilkinson CW, McTiernan A, Cholerton BA, Plymate SR, Fishel MA, Watson GS, Duncan GE, Mehta PD, Craft S (2010) Aerobic exercise improves cognition for older adults with glucose intolerance, a risk factor for Alzheimer's disease. J Alzheimers Dis 22, 569-579
104. Teixeira-Lemos E, Nunes S, Teixeira F, Reis F (2011) Regular physical exercise training assists in preventing type 2 diabetes development: Focus on its antioxidant and antiinflammatory properties. Cardiovasc Diabetol 10, 12
105. Archer T (2011) Physical exercise alleviates debilities of normal aging and Alzheimer's disease. Acta Neurol Scand 123, 221-238
106. Black MA, CableNT, Thijssen DH, Green DJ (2009) Impact of age, sex, and exercise on brachial artery flow-Mediated dilatation. Am J Physiol Heart Circ Physiol 297, H1109-H1116
107. Ainslie PN, Hamlin M, Hellemans J, Rasmussen P, Ogoh S (2008) Cerebral hypoperfusion during hypoxic exercise following two different hypoxic exposures: Independence from changes in dynamic autoregulation and reactivity. Am J Physiol Regul Integr Comp Physiol 295, R1613-1622
108. Colbert LH, Visser M, Simonsick EM, Tracy RP, Newman AB, Kritchevsky SB, Pahor M, Taaffe DR, Brach J, Rubin S, Harris TB (2004) Physical activity, exercise, and inflammatory markers in older adults: Findings from the Health, Aging and Body Composition Study. J Am Geriatr Soc 52, 1098-1104
109. Kampus P, Kals J, Unt E, Zilmer K, Eha J, Teesalu R, Normak A, Zilmer M (2008) Association between arterial elasticity, C-reactive protein and maximal oxygen consumption in well-Trained cadets during three days extreme physical load: A pilot study. Physiol Meas 29, 429-437
110. Gomez-Pinilla F, Vaynman S, Ying Z (2008) Brain-Derived neurotrophic factor functions as a metabotrophin to mediate the effects of exercise on cognition. Eur J Neurosci 28, 2278-2287
111. Geda YE, Roberts RO, Knopman DS, Christianson TJ, Pankratz VS, Ivnik RJ, Boeve BF, Tangalos EG, Petersen RC, Rocca WA (2010) Physical exercise, aging, and mild cognitive impairment: A population-based study. Arch Neurol 67, 80-86
112. Andel R, Crowe M, Pedersen NL, Fratiglioni L, Johansson B, Gatz M (2008) Physical exercise at midlife and risk of dementia three decades later: A population-based study of Swedish twins. J Gerontol A Biol Sci Med Sci 63, 62-66
113. Liang KY, Mintun MA, Fagan AM, Goate AM, Bugg JM, Holtzman DM, Morris JC, Head D (2010) Exercise and Alzheimer's disease biomarkers in cognitively normal older adults. Ann Neurol 68, 311-318
114. TeixeiraCV, GobbiLT, Corazza DI, Stella F, Costa JL, Gobbi S (2012) Non-Pharmacological interventions on cognitive functions in older people with mild cognitive impairment (MCI). Arch Gerontol Geriatr 54, 175-180
115. Morris JC, Cummings J (2005) Mild cognitive impairment (MCI) represents early-Stage Alzheimer's disease. J Alzheimers Dis 7, 235-239; discussion 255-262
116. LautenschlagerNT, Cox KL, Flicker L, Foster JK, van Bockxmeer FM, Xiao J, Greenop KR, Almeida OP (2008) Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: A randomized trial. JAMA 300, 1027-1037
117. Liu ZP, Wang Y, Zhang XS, Chen L (2012) Network-based analysis of complex diseases. IET Syst Biol 6, 22-33